🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced today

Find Clinical Trials for Your Rare Disease

12572+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Showing 20 of 12572 recruiting trials

Phase 4RecruitingNCT02523092

Use of CXCL9 as a Biomarker of Acthar Efficacy

👨‍⚕️ Laura Koth, MD, University of California, San Francisco📍 1 site📅 Started Nov 2022View details ↗
Phase 2RecruitingNCT05924100

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

🏥 Associazione Qol-one📍 23 sites📅 Started Nov 2022View details ↗
Phase 2RecruitingNCT05641935

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

🏥 john eisenbrey📍 1 site📅 Started Nov 2022View details ↗
RecruitingNCT05600842

De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

👨‍⚕️ Eric Chen, MD, Chao Family Comprehensive Cancer Center📍 1 site📅 Started Nov 2022View details ↗
Phase 2Enrolling by InvitationNCT05219929

Tetracycline Treatment Tolerability Trial

👨‍⚕️ John N. Aucott, MD, Johns Hopkins University📍 1 site📅 Started Nov 2022View details ↗
Phase 3RecruitingNCT05608213

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started Nov 2022View details ↗
RecruitingNCT07181070

The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor

👨‍⚕️ Giovanni Aprea, Prof., Federico II University📍 1 site📅 Started Nov 2022View details ↗
Phase 3RecruitingNCT05357846

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

👨‍⚕️ HONG YANG, Sun Yat-Sen University Cancer Center📍 1 site📅 Started Nov 2022View details ↗
RecruitingNCT06462430

PTEN Hamartoma Tumor Syndrome Pediatric Patient Registry

👨‍⚕️ Hande Kaymakcalan Celebiler, MD, Yale University📍 1 site📅 Started Nov 2022View details ↗
Phase 2RecruitingNCT05180097

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

👨‍⚕️ Kerry Savage, BCCA-Vancouver Cancer Centre📍 18 sites📅 Started Nov 2022View details ↗
Phase 4RecruitingNCT05305287

Quantifying Hepatic Mitochondrial Fluxes in Humans

👨‍⚕️ Luke Norton, PhD, The University of Texas Health Science Center at San Antonio📍 2 sites📅 Started Nov 2022View details ↗
Phase 1RecruitingNCT05500807

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

👨‍⚕️ Jonathan C Roberts, MD, Bleeding and Clotting Disorders Institute📍 9 sites📅 Started Nov 2022View details ↗
NARecruitingNCT05584722

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

👨‍⚕️ Evan Brittain, MD, Vanderbilt Medical Center📍 1 site📅 Started Nov 2022View details ↗
Enrolling by InvitationNCT05812339

Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls

👨‍⚕️ Christopher N Andrews, MD MSc FRCPC, University of Calgary📍 1 site📅 Started Nov 2022View details ↗
NARecruitingNCT05600465

Behavioral Activation + Occupational Therapy: An Innovative Intervention for Empowered Self-Management of Multiple Chronic Conditions

👨‍⚕️ Tara Klinedinst, University of Oklahoma📍 1 site📅 Started Nov 2022View details ↗
Phase 1, PHASE2Enrolling by InvitationNCT05577312

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

👨‍⚕️ Xiaochen Wang, PhD, Bioray Laboratories📍 4 sites📅 Started Nov 2022View details ↗
Phase 2RecruitingNCT06122493

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

🏥 Ruijin Hospital📍 1 site📅 Started Nov 2022View details ↗
RecruitingNCT05593679

A Multi-center Cardiac PYP Scan Registry in Taiwan

👨‍⚕️ Yen-Wen Wu, Far Eastern Memorial Hospital📍 1 site📅 Started Nov 2022View details ↗
Phase 1, PHASE2RecruitingNCT05092451

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

👨‍⚕️ David Marin, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Nov 2022View details ↗
Phase 2RecruitingNCT05846750

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

👨‍⚕️ Shuhua Yi, Dr, Institute of Hematology & Blood Diseases Hospital, Chinese📍 1 site📅 Started Nov 2022View details ↗
← PreviousPage 447 of 629Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →